These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2541260)

  • 1. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen.
    Gandara DR; Wold H; Perez EA; Deisseroth AB; Doroshow J; Meyers F; McWhirter K; Hannigan J; De Gregorio MW
    J Natl Cancer Inst; 1989 May; 81(10):790-4. PubMed ID: 2541260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group.
    Gandara DR; Perez EA; Wold H; Caggiano V; Malec M; Ahn DK; Meyers F; Carlson RW
    Cancer Chemother Pharmacol; 1990; 27(3):243-7. PubMed ID: 2176134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer.
    Gandara DR; DeGregorio MW; Wold H; Wilbur BJ; Kohler M; Lawrence HJ; Deisseroth AB; George CB
    J Clin Oncol; 1986 Dec; 4(12):1787-93. PubMed ID: 3023557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
    Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
    J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer.
    Murray N; Coppin C; Coldman A; Pater J; Rapp E
    J Clin Oncol; 1994 Nov; 12(11):2333-9. PubMed ID: 7964949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum/oral etoposide therapy in non-small cell lung cancer.
    Furuse K
    Oncology; 1992; 49 Suppl 1():63-9; discussion 70. PubMed ID: 1323814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
    von Pawel J; Wagner H; Niederle N; Heider A; Koschel G; Hecker D; Hanske M
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):47-50. PubMed ID: 9007121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
    Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
    Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study.
    Gandara DR; Valone FH; Perez EA; Deisseroth AB; Roach M; Ahn DK; Phillips T
    Int J Radiat Oncol Biol Phys; 1991 May; 20(5):1047-52. PubMed ID: 1850719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
    Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Splinter TA; Sahmoud T; Festen J; van Zandwijk N; Sörenson S; Clerico M; Burghouts J; Dautzenberg B; Kho GS; Kirkpatrick A; Giaccone G
    J Clin Oncol; 1996 Jan; 14(1):127-34. PubMed ID: 8558187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.